NEW YORK, Aug. 19 (GenomeWeb News) - Galileo Genomics has purchased two of Illumina's BeadStation 500GX genotyping systems for its disease gene discovery programs in an agreement that could be worth $1.5 million to Illumina, the companies said today.
Under the agreement, Galileo will use the genotyping systems in five disease gene association studies that use DNA samples from the Quebec Founder population, a pool of 6 million individuals of French descent in Quebec. Illumina will receive rights to diagnostics that could be developed from biomarkers discovered in the program, as well as from Galileo's existing gene discovery program for osteoarthritis.
The first disease that Galileo is studying under this program is the chronic gastrointestinal disorder Crohn's disease. The company has already conducted genome-wide scans of 1,500 individuals within the Quebec Founder population to identify candidate regions associated with the disease, and will now analyze SNPs within that region, the companies said. The companies did not specify the four other diseases to be studied under the program.